Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26932077 | 0.85 | GABRA5 (0.39) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26932034 | 0.81 | GABRA5 (0.38) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL3011102 | 0.81 | NR1H4 (0.41) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21996265 | 0.78 | PPARG (0.41) | HDAC3HDAC1HDAC2NCOR2SSTR4 | |
| SCHEMBL24621110 | 0.77 | GABRA5 (0.43) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2138873 | 0.76 | GABRA1 (0.42) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL24061763 | 0.74 | L3MBTL1 (0.50) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4404331 | 0.73 | SMN1; SMN2 (0.38) | ACACB | |
| SCHEMBL15688014 | 0.72 | PTGES (0.53) | HDAC3HDAC1HDAC2NCOR2PTGES | |
| SCHEMBL9805558 | 0.72 | GABRA1 (0.51) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3144308-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3144308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | GABRA5 228/4885GABRA1 300/4885GABRG2 852/4885 |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | GABRA5 531/4885GABRA1 438/4885GABRG2 919/4885 |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | GABRA5 228/4885GABRA1 300/4885GABRG2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.